Table 4.
Univariate and Multivariate Analysis of Prognostic Factors Affecting PFS and OS
| Parameters | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P value | HR | 95% CI | P value | |
| PFS | ||||||
| DEB-TACE | 0.387 | 0.229–0.652 | <0.001 | 0.384 | 0.228–0.647 | <0.001 |
| Male | 1.195 | 0.657–2.172 | 0.559 | — | — | — |
| Previous treatment | 1.128 | 0.676–1.881 | 0.646 | — | — | — |
| Hepatitis B or C virus | 1.018 | 0.614–1.688 | 0.945 | — | — | — |
| Tumor size >5 cm | 1.637 | 0.996–2.691 | 0.052 | 1.665 | 1.013–2.737 | 0.044 |
| Child-Pugh B class | 0.918 | 0.451–1.868 | 0.813 | — | — | — |
| BCLC B stage | 1.100 | 0.661–1.831 | 0.713 | — | — | — |
| AFP >400 μg/L | 1.053 | 0.626–1.770 | 0.846 | — | — | — |
| Repeated TACE | 0.698 | 0.372–1.309 | 0.263 | — | — | — |
| AEs | 1.005 | 0.617–1.638 | 0.983 | — | — | — |
| OS | ||||||
| DEB-TACE | 0.505 | 0.263–0.973 | 0.041 | 0.246 | 0.106–0.568 | <0.001 |
| Male | 1.080 | 0.516–2.260 | 0.838 | — | — | — |
| Previous treatment | 0.801 | 0.429–1.496 | 0.486 | — | — | — |
| Hepatitis B or C virus | 0.709 | 0.379–1.328 | 0.283 | — | — | — |
| Tumor size >5 cm | 1.317 | 0.713–2.433 | 0.379 | — | — | — |
| Child-Pugh B class | 1.615 | 0.710–3.672 | 0.253 | — | — | — |
| BCLC B stage | 1.320 | 0.663–2.630 | 0.430 | — | — | — |
| AFP >400 μg/L | 0.590 | 0.289–1.202 | 0.146 | — | — | — |
| Repeated TACE | 0.270 | 0.132–0.555 | <0.001 | 0.113 | 0.044–0.291 | <0.001 |
| AEs | 0.994 | 0.539–1.834 | 0.985 | — | — | — |
Abbreviations: HR, hazard ratio; CI, confidence interval; PFS, progression-free survival; DEB-TACE, drug-eluting beads transarterial chemoembolization; BCLC, Barcelona clinic liver cancer; AFP, α-fetoprotein; TACE, transarterial chemoembolization; AEs, adverse events; OS, overall survival.